Microglia activation is observed in various neurodegenerative diseases. Recent advances in
single-cell technologies have revealed that these reactive microglia were with high spatial …

Background The second consensus criteria for the diagnosis of multiple system atrophy
(MSA) are widely recognized as the reference standard for clinical research, but lack …

Abnormal α-synuclein aggregation is a key pathological feature of a group of
neurodegenerative diseases known as synucleinopathies, which include Parkinson's …

There is poor knowledge about the clinical effects of Lewy body (LB) pathology in patients
with cognitive impairment, especially when coexisting with Alzheimer's disease (AD) …

Synucleinopathies are clinically and pathologically heterogeneous disorders characterized
by pathologic aggregates of α-synuclein in neurons and glia, in the form of Lewy bodies …

Synucleinopathies, which include multiple system atrophy (MSA), Parkinson's disease,
Parkinson's disease with dementia and dementia with Lewy bodies (DLB), are human …

A positron emission tomography (PET) tracer detecting α-synuclein pathology will improve
the diagnosis, and ultimately the treatment of α-synuclein-related diseases. Here we show …

The clinical diagnosis of synucleinopathies, including Parkinson's disease (PD), dementia
with Lewy bodies (DLB), and multiple system atrophy (MSA), is challenging, especially at an …

Importance Finding a reliable diagnostic biomarker for the disorders collectively known as
synucleinopathies (Parkinson disease [PD], dementia with Lewy bodies [DLB], multiple …

Animal studies implicate meningeal lymphatic dysfunction in the pathogenesis of
neurodegenerative diseases such as Alzheimer's disease and Parkinson's disease (PD) …